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Long noncoding RNA lncTCF7, induced
by IL-6/STAT3 transactivation, promotes
hepatocellular carcinoma aggressiveness
through epithelial-mesenchymal transition
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Abstract
Background: Accumulating evidence suggests the pro-inflammatory cytokine interleukin-6 (IL-6) in tumor
microenvironment may promote the development of hepatocellular carcinoma (HCC). However, the underlying
mechanism remains largely unknown.
Methods: The expression and promoter activity of lncTCF7 were measured by quantitative real-time polymerase
chain reaction (qRT-PCR) and luciferase reporter assay. The function of the STAT3 binding site in the lncTCF7
promoter region was tested by luciferase reporter assay with nucleotide substitutions. The binding of STAT3 to the
lncTCF7 promoter was confirmed by chromatin immunoprecipitation assay (CHIP) in vivo. The effects of decreasing
STAT3 with small interference RNA and inhibiting STAT3 activation by small molecular inhibitor on lncTCF7
expression were also determined.
Results: We demonstrate that IL-6 could induce lncTCF7 expression in a time- and dose-dependent manner, and
we showed that IL-6 transcriptionally activated the expression of lncTCF7 in HCC cells by activating STAT3, a
transcription activator which binds to promoter regions of lncTCF7. Furthermore, knocking-down STAT3 and
inhibiting STAT3 activation reduced lncTCF7 expression. Importantly, RNA interference-based attenuation of lncTCF7
prevented IL-6-induced EMT and cell invasion.
Conclusion: Thus, these data provides evidence to the existence of an aberrant IL-6/STAT3/ lncTCF7 signaling axis
that leads to HCC aggressiveness through EMT induction, which could be novel therapeutic targets in malignancies.
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Introduction
Liver cancer is the fifth-most common solid tumor
worldwide and the second most frequent cause of
cancer-related death in China [1, 2]. Hepatocellular
carcinoma (HCC) represents the major histological
subtype and accounts for about 78 % cases of primary
liver cancer [2]. In spite of the recent advances in the
management of HCC, the 5-year survival rate of HCC
remains poor, at approximately 50 % (range, 17–69) [3].
The high incidence of cancer recurrence and metastasis
is still the main obstacle in the treatment of HCC [1, 2].
Although remarkable progress have been made in the
knowledge of HCC tumorigenesis, the precise details of
the molecular mechanisms underlying HCC carcinogenesis
remain to be elucidated [4, 5].
Increasing evidence has established a linked between
chronic inflammation and liver cancer risk in epidemio-
logical studies [6–8], and several pro-inflammatory
cytokines released from infiltrating inflammatory cells
and other cells in the microenvironment have been
suggested to regulate HCC carcinogenesis [9–11]. In
particular, interleukin-6 (IL-6) and its intracellular sig-
naling molecule signal transducer and activator of tran-
scription 3 (STAT3) seem to play a vital role in bridging
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chronic inflammation to HCC progression [9, 12]. Fur-
thermore, IL-6 levels in cancer tissues and serum are
elevated in HCC patients, and are correlated with tumor
metastasis and reduced patient survival [13, 14].
Long noncoding RNAs (lncRNAs) are a class of novel
noncoding RNAs, defined as transcripts longer than 200
nucleotides (nt) with limited protein-coding potential
[15]. Although once regarded as “transcriptional noise”,
lncRNAs have been demonstrated to take a part in a
variety of cellular processes, including carcinogenesis
[16–19]. Alterations in a number of lncRNAs have been
shown to exhibit tumor-suppressive or pro-oncogenic
activities in HCC, including Linc00974 [20], HOTAIR
[21], H19 [22], DANCR [23], lncTCF7 [16], Dreh [24],
lncRNA MVIH [25], lncRNA-HEIH [26], HULC [27],
LET [28], lncRNA-ATB [11], and PVT-1 [29]. However,
the effect of IL-6 on lncRNAs remains largely unknown.
The epithelial-mesenchymal-transition (EMT) is a well-
coordinated process that take places during embryonic
development and a pathological feature in tumorigen-
esis [30, 31]. During this process, the epithelial pheno-
type cells lose expression of membranous epithelial
marker E-cadherin and other components of cell to cell
junctions and adopt a mesenchymal phenotype [32].
The EMT process has been demonstrated to play an
important role in cancer invasion, metastasis, therapeutic
resistance and expansion of the population of CSCs [32].
As lncTCF7 is necessary for liver CSC self-renewal and
tumor propagation, we hereby propose a novel IL-6/
STAT3/lncTCF7 signaling axis that may contribute to the
EMT program and self-renewal of CSCs.
In this study, we sought to investigate the effects of
IL-6 on the expression and function of HCC-specific
lncRNAs. Our data provides solid evidence to verify that
lncTCF7 is significantly upregulated in response to IL-6
stimulation and plays a central role in IL-6-induced
epithelial-mesenchymal transition process of HCC cells.
We demonstrated that IL-6 transcriptionally activated
the expression of lncTCF7 in HCC cells by activating
STAT3, a transcription activator which binds to promoter
regions of lncTCF7. Our study propose the existence
of an aberrant IL-6/STAT3/ lncTCF7 signaling axis
leading to HCC aggressiveness through EMT induc-




Two HCC cell lines (SK-Hep-1 and BEL-7402) were
obtained from the Institute of Biochemistry and Cell
Biology of the Chinese Academy of Sciences (Shanghai,
China). The cell lines were grown in DMEM (Gibco
BRL, Grand Island, NY, USA) supplemented with 10 %
fetal bovine serum (FBS, HyClone, Camarillo, CA, USA)
as well as 100 U/ml penicillin and 100 μg/ml streptomycin
(Invitrogen, Carlsbad, CA, USA). Cells were maintained in
a humidified incubator at 37 °C in the presence of 5 %
CO2. All cell lines have been passaged for fewer than
6 months and tested routinely by Hoechst DNA
staining to ensure that there is no mycoplasma
contamination.
Antibodies and reagants
Recombinant IL-6 and negative control Ab were pur-
chased from R&D Systems. All other reagents used were
of analytical grade or the highest grade available. Anti-
bodies against E-cadherin, vimentin, STAT3, p-STAT3
(Y705) and β-Actin were obtained from Abcam.
RNA extraction and quantitative real-time PCR
Total RNA was extracted from HCC cells utilizing
Trizol reagent (Invitrogen, Carlsbad, CA, USA)
according to the manufacturer’s instructions. cDNA
was transcribed using AMV reverse transcriptase
(Promega, Madison, Wisconsin, USA). The quantita-
tive real-time polymerase chain reaction (qRT-PCR)
was achieved on ABI 7500 system (Applied Biosystems,
CA, USA). GAPDH was uesd as an internal control, and
mRNA values of target gene was normalized to GAPDH.
The relative expression fold change of mRNAs was
calculated with the 2-ΔΔCt method. The results are
representative of at least three independent experi-
ments. qRT-PCR results were expressed and analyzed
relative to CT (threshold cycle) values, and then
converted to fold changes. The sequences of the
qRT-PCR primers used in this study were listed in
Table 1.
Western blot analysis
The harvested HCC cells were centrifuged at 2000 rpm
for 4 min. The total cellular proteins were lysed in RIPA
buffer (Cell Signaling Technology) supplemented with
protease inhibitors. The lysates were collected and
subjected to ultrasonication and centrifugation. The
supernatants were collected, and the protein concentra-
tions were determined using BCA Protein Assay Kit
(Pierce). Equal amounts (30–40 μg) of proteins were
separated by 8–12 % SDS-polyacrylamide gel electro-
phoresis and transferred to a PVDF Immobilon-P mem-
brane (Millipore). The membrane was blocked with 5 %
nonfat milk in TBST and then probed with indicated
primary antibodies at 4 °C overnight with gentle shaking.
The membranes were washed with TBST (3 × 5 min),
incubated in secondary antibodies for 1 h at room
temperature. Antibody-bound proteins were detected by
BeyoECL Plus kit. Intensity of the bands was quantified
by densitometry (Image J 1.47 software) and normalized
to the corresponding β-Actin bands.
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The primary antibodies used in these experiments in-
clude rabbit polyclonal anti-human STAT3 (1:1000,
Abcam), p-STAT3 (Y705) (1:1000, Abcam), rabbit mono-
clonal anti-human E-cadherin (1:500, Epitomics, Burlin-
game, CA, USA), rabbit monoclonal anti-human Vimentin
(1:500, Epitomics), and rabbit polyclonal anti-human Actin
(1:4,000, Abcam). HRP-conjugated goat anti-rabbit IgG
antibody (Abcam) was used as the secondary antibody.
Cell transfection
LncTCF7 siRNA, STAT3 siRNA and Control siRNA
were purchased from Qiagen, Hilden, Germany. Cells
Table 1 Primer and siRNA list
mRNA/gene promoter sequence (5′-3′) Experimental use
linc00974 5′-TCTAACGTGCCTGGGACCTA-3′(forward) Real-time PCR
5′-AAATGCCTACCGCCAGTTCA-3′(reverse)
HOTAIR 5′-CAGTGGGGAACTCTGACTCG-3′(forward) Real-time PCR
5′-GTGCCTGGTGCTCTCTTACC-3′(reverse)
H19 5′-ACTCAGGAATCGGCTCTGGAA-3′(forward) Real-time PCR
5′-CTGCTGTTCCGATGGTGTCTT-3′(reverse)
DANCR 5′-GCGCCACTATGTAGCGGGTT-3′(forward) Real-time PCR
5′-TCAATGGCTTGTGCCTGTAGTT-3′(reverse)
lncTCF7 5′-AGGAGTCCTTGGACCTGAGC-3′(forward) Real-time PCR
5′-AGTGGCTGGCATATAACCAACA-3′(reverse)
Dreh 5′-CCTGTATGACGATGGAGCCT-3′(forward) Real-time PCR
5′-TGACACATTTGCGATGGGTAT-3′(reverse)
lncRNA MVIH 5′-GAGACAGGATTTAGCCGTGTTG-3′(forward) Real-time PCR
5′-AGCACTTTGGAAGGCTTAGACA-3′(reverse)
lncRNA-HEIH 5′-CCTCTTGTGCCCCTTTCTT-3′(forward) Real-time PCR
5′-ATGGCTTCTCGCATCCTAT-3′(reverse)
HULC 5′-CCATCCAATCGGTAGTAGCG-3′(forward) Real-time PCR
5′-TCCAGAAAGAGGGAGTTG-3′(reverse)
LET 5′-CCTTCCTGACAGCCAGTGTG-3′(forward) Real-time PCR
5′-CAGAATGGAAATACTGGAGCAAG-3′ (reverse)
lncRNA-ATB 5′-TCTGGCTGAGGCTGGTTGAC-3′(forward) Real-time PCR
5′-ATCTCTGGGTGCTGGTGAAGG-3′(reverse)
PVT-1 5′-GCTGCAAGGTCAAGATGGTT-3′(forward) Real-time PCR
5′-GCTGGGTGGCGTTCTATC-3′(reverse)
β-actin 5′-TCCCTGGAGAAGAGCTACGA-3′(forward) Real-time PCR
5′-AGCACTGTGTTGGCGTACAG-3′(reverse)
GADPH 5′-GCATCCTGGGCTACACTG-3′(forward) Real-time PCR
5′-TGGTCGTTGAGGGCAAT-3′(reverse)
lncTCF7 promoter 5′-AGCCAGACAGAAGAGTGGA-3′ (forward) ChIP-PCR
5′-TGGGATGGGGATGTCAGAAC-3′ (reverse)
lncTCF7 promoter SIE3 5′-ACTGGTACCTAAGCGGAGAGAGTCCCACACAGG-3′ (forward) Site-directed mutagenesis
5′-ACTAAGCTTGAGTCAGAGTTCCCCAC-3′ (reverse)
lncTCF7 promoter SIE4 5′-ACTGGTACCTAAGCGGAGAGAGTCCCACACAGG-3′(forward) Site-directed mutagenesis
5′-ACTAAGCTTGAGTCAGAGTTCCCCAC-3′ (reverse)
lncTCF7 siRNA-1 5′-AGCCAACATTGTTGGTTAT-3′, RNA interference
lncTCF7 siRNA-2 5′-CACCTAGGTGCTCACTGAA-3′ RNA interference
STAT3 siRNA 5′-AAAUCCAGAACCCUCUGACAUUUGC-3′ RNA interference
siRNA control 5′-UUCUCCGAACGUGUCACGUTT-3′ RNA interference
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were transfected using Lipofectamine 2000 (Invitrogen)
according to the manufacturer’s instructions. Forty-eight
hours after transfection, cells were harvested and
subjected to qRT-PCR or western blot analyses.
Immunofluorescence analysis
IL-6 treated cell layers on glass coverslips. For mem-
brane staining (E-cadherin), cells were fixed with
100 % methanol for 15 min. For intracellular staining
(Vimentin), cells were fixed for 15 min with 4 % (wt/
vol) paraformaldehyde in PBS, permeabilized with
0.5 % Triton X-100 in PBS for 2 min, incubated with
5 % bovine serum albumin in PBS for 20 min at room
temperature, and then probed with primary antibody
at 4 °C overnight. After washing in PBS, the cells were
incubated with FITC-conjugated secondary antibodies
(Jackson ImmunoResearch, West Grove, PA) for 1 h
at room temperature. The nuclei were stained with
4,6-diamidino-2-phenylindole (DAPI). The slides were
mounted and visualized using a fluorescence micro-
scope (AX70, Olympus, Tokyo, Japan). Antibody dilu-
tions of 1:300 were used for E-cadherin (Abcam), and
Vimentin (Cell Signaling Technology).
Chromatin immunoprecipitation
HCC cells were serum-starved overnight and treated
with 50 ng/ml IL-6 for 1 h. Chromatin was cross-linked
with 1 % formaldehyde for 10 min. After cell lysis, the
chromatin was sonicated to obtain a DNA smear with
an average size of 500 bp. After centrifugation, the
supernatants were subjected to immunoprecipitation
overnight with antibodies against STAT3 at 4 °C, or with
isotype rabbit IgG at 4 °C overnight. Chromatin-
antibody complexes were isolated using Protein A/G
PLUS Agarose (Santa Cruz). The crosslinks for the
enriched and the input DNA were reversed and the
DNA was cleaned by RNase A (0.2 mg/mL) and protein-
ase K (2 mg/mL) before phenol/chloroform-purification.
PCR was employed to analyzed the specific sequences
from immunoprecipitated and input DNA utilizing the
following primer sequences for lncTCF7 promoter region:
5′-AGCCAGACAGAAGAGTGGA-3′ (forward) and 5′-TG
GGATGGGGATGTCAGAAC 3′ (reverse). The results are
representative of at least three independent experiments.
Luciferase reporter assay
The genomic regions neighboring the promoter region
of human lncTCF7 gene were amplified by PCR and
then inserted into the pGL3 vector. The reporter
constructs were generated by subsequent PCR-based
cloning and they contained various lengths of lncTCF7
promoter or mutated STAT3 binding sites. The lucif-
erase reporter assay was performed by transfecting the
indicated cell lines with the reporter construct
containing wild-type (wt) or mutant (mut) STAT3
expression vectors. Each sample was cotransfected
with the pRL-SV40 vector as an internal control for
transfection efficiency. At 24 h post-transfection, cells
were incubated with IL-6 50 ng/ml for 6 h and the
luciferase activities were measured utilizing the Dual-
Luciferase Reporter Assay System (Promega, Madison,
WI) and the luminometer (LB 9507, Berthold, Bad
Wildbad, Germany). The relative luciferase expression
equals the expression of Renilla luciferase divided by
the expression of firefly luciferase. and all the experi-
ments were carried out in triplicate.
Cell invasion assay
The cancer cell invasion assay was performed in 24-well
transwell plates (Costar, Cambridge, MA) with 8 μm-pore
inserts precoated with Matrigel (40 μl, BD Biosciences,
San Jose, CA). Briefly, cells (1 × 105) in serum-free
medium were added into a culture insert, whereas
complete medium (supplemented with 10 % FBS) with or
without 50 ng/ml IL-6 was applied to the lower com-
partment. After incubation for 48 h, cells on the
upper surface of the filter were scraped and washed
away, whereas the undersurface adherent cells were
fixed in 4 % formaldehyde and stained with 0.05 %
crystal violet for 2 h. The air-dried filter membrane
was viewed under a microscope and three random
fields were selected for cell counting.
Statistical analysis
All statistical analyses were performed using SPSS 17.0
(SPSS, Chicago, USA). The data are representative of
three independent experiments and are presented as
mean value ± standard deviation. Statistical evaluations
were analyzed using unpaired student’s t-test. A two-
sided p value of less than 0.05 was considered to be
statistically significant.
Results
lncRNAs are elevated in HCC cells exposed to IL-6
To determine the effect of IL-6 on the expression of HCC
specific lncRNAs, qRT-PCR analysis was performed in
HCC cell line SK-Hep1 exposed to IL-6 50 ng/ml for 24 h.
As demonstrated in Fig. 1a, several HCC specific lncRNAs
were significantly dysregulated in response to IL-6 stimu-
lation. Among them, lncTCF7 was most strongly dysregu-
lated. Furthermore, IL-6 can increase the expression of
lncTCF7 in a dose- and time-dependent manner in both
SK-Hep1 and BEL-7402 cells (Fig. 1b, c) confirming that
its expression can be stimulated by IL-6.
Effect on IL-6 on the activation of STAT3 in HCC cells
IL-6 has been reported to be a pro-inflammatory cyto-
kine characterized as a potent activator of STAT3 [9].
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Accordingly, we examined the activation status of
STAT3 in response to IL-6 treatment in HCC cells. As
illustrated in Fig. 2a, IL-6 induced dose-dependent
STAT3 phosphorylation (Y705). Expression of pSTAT3
(Y705) was elevated in the cells treated with IL-6 for 4 h
and peaked in cells treated with 50 ng/ml IL-6. In
contrast, IL-6 did not affect the level of unphosphory-
lated STAT3. In a time-course experiment, STAT3
(Y705) phosphorylation peaked after 2 h of IL-6 treat-
ment (Fig. 2b). The level of STAT3 (Y705) phosphoryl-
ation declined after the cells were treated with IL-6
for 4 h. We confirmed that IL-6 induced phosphoryl-
ation of STAT3 in a dose- and time-dependent man-
ner in SK-Hep1 cells; moreover, the activation of
STAT3 was abrogated by pretreatment with LLL12, an
inhibitor of STAT3 (Fig. 2c). Simultaneously, the up-
regulation of lncTCF7 induced by IL-6 was obviously
attenuated by pretreatment with the inhibitor (Fig. 2d).
In addition, siRNA-mediated STAT3 knockdown
significantly ameliorated the IL-6 induced lncTCF7
expression in HCC cells (Fig. 2e, f ). These data sug-
gest that IL-6 induced STAT3 activation is vital in the
upregulation of lncTCF7.
STAT3 binds directly to the promoter region of lncTCF7
upon IL-6 stimulation
With the help of online bioinformatical software
programs MatInspector (www.genomatix.de/online_help/
help_matinspector/matinspector_help.html) and TFSEARCH
(www.brc.jp/research/db/TFSEARCH.html) in the pro-
moter region of lncTCF7, we predicted that the promoter
sequence of the lncTCF7 gene harbored 7 potential
STAT-inducible elements (SIEs). Serial truncations of the
lncTCF7 gene promoter were generated created based on
the location of the STAT3-binding sites to identify the
transcriptional regulatory region responsive to IL-6/
STAT3 signaling (Fig. 3a). Luciferase reporter assay dem-
onstrated that the region between −720 and −476 on the
lncTCF7 promoter was responsible for STAT3-mediated
activation (Fig. 3b). This region contained two potential
SIEs (SIE3 and SIE4) on the lncTCF7 promoter. Mutation
in SIE3 or SIE4 markedly reduced the reporter activity
induced by IL-6 (Fig. 3c). To confirm this finding, a ChIP
assay was employed to confirm the interaction of STAT3
with the promoter regions of lncTCF7 in SK-Hep1 cells
exposed to IL-6. ChIP-PCR results demonstrated that
STAT3 directly bounds to the lncTCF7 promoter region
upon IL-6 stimulation (Fig. 3d). Our data suggest that
IL-6-activated STAT3, which transcriptionally activates
lncTCF7 by binding directly to the promoter.
lncTCF7 is involved in IL-6 induced epithelial-mesenchymal
transition, invasion and mobility of HCC cells
As previous studies have demonstrated that IL-6 effi-
ciently induced epithelial-mesenchymal transition
(EMT) in cancer [12, 33], we firstly explored the effect
of IL-6 on EMT in HCC cells. After exogenous IL-6
treatment, SK-Hep1 cells became more spindle-shaped
and came up with a mesenchymal phenotype. With the
immunofluorescence analysis, IL-6 exposure resulted in
an obvious downregulation in the expression of membran-
ous epithelial marker E-cadherin and a great upregulation
in the expression of cytoplasmic mesenchymal marker
Vimentin (Fig. 4a). The western blot analysis confirmed
the data from the immunofluorescence analysis (Fig. 4b).
It suggests that IL-6 can induce EMT in HCC cells.
We would like to explore whether lncTCF7 is
involved in IL-6 induced EMT in HCC cells. We mod-
ulated the expression level of lncTCF7 through RNA
interference experiments. 48 h after transfection, qRT-
PCR analysis of lncTCF7 expression levels was performed.
Fig. 1 IL-6 increases the level of HCC specific lncRNA mRNA in HCC
cells. a Relative mRNA levels of HCC specific lncRNAs in SK-Hep1
cells treated with IL-6 50 ng/ml for 24 h (normalized to GAPDH).
b Treatment of SK-Hep-1 cells with IL-6 induced the expression
of lncTCF7 in a time- and dose-dependent manner. qRT-PCR analysis
of lncTCF7 in SK-Hep-1 cells incubated with gradient concentrations of
IL-6 for 24 h. qRT-PCR analysis of lncTCF7 in SK-Hep-1 cells incubated
with IL-6 50 ng/ml for different periods of time. c Similar to
effects seen in SK-Hep-1 cells, IL-6 also induced the expression
of lncTCF7 in BEL-7402 cells. Data represent the mean ± S.D.
from three independent experiments.*p < 0.05.*p < 0.05
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As demonstrated in Fig. 5a, lncTCF7 was significantly
knocked down by silncTCF7-2, the most effective
siRNA. The mesenchymal-like morphological conver-
sion stimulated by IL-6 was substantially attenuated
after transfection of lncTCF7 siRNA (Fig. 5b). The
expression changes in EMT markers were blunted with
lncTCF7 knockdown in SK-Hep1 cells both at the tran-
script and protein levels (Fig. 5c, d).
EMT process has been consistently reported to be
associated with increased cancer cell invasion [9, 12].
Thus, we hypothesize that IL-6 can enhance cancer
cell invasiveness at least partially via upregulating
lncTCF7. The acquisition of invasive capacity in response
to IL-6 stimulation was ameliorated by lncTCF7 silen-
cing (Fig. 6). The above results indicate that lncTCF7
transactivated by STAT3 is essential for IL-6 induced
EMT process and more malignant phenotypes in
HCC cells.
Discussion
There has been an established link between chronic inflam-
mation and cancer risk, and various pro-inflammatory
cytokines contribute to the transformation of cancer
cells into more aggressive phenotypes through the
regulation of oncogenes, which enhance the develop-
ment and progression of cancer [6, 34]. In particular,
IL-6/STAT3 signaling axis seem to play a vital role in
bridging chronic inflammation to HCC progression
[9, 12]. However, whether lncRNAs are also involved
in this process remains largely unknown. In the present
Fig. 2 IL-6 induces STAT3 (Y705) phosphorylation. a IL-6 induces STAT3 (Y705) phosphorylation in a dose-dependent manner. SK-Hep-1 cells were
treated with the indicated doses of IL-6 for 4 h and analyzed by western blotting using the indicated antibodies. pSTAT3, Y705-phosphorylated
STAT3. b Time-course studies of IL-6-induced STAT3 (Y705) phosphorylation. SK-Hep-1 cells were treated with 50 ng/ml IL-6 for the indicated
times. Total cellular proteins were prepared for western blotting at the end of each treatment. c STAT3 inhibition blocked IL-6-induced STAT3
activation. SK-Hep-1 cells were cultured in the presence or absence of 5 μM LLL12, a STAT3 inhibitor for 2 h and then with 50 ng/ml IL-6 for an
additional 12 h. Total cellular proteins were prepared for western blotting analysis. d STAT3 inhibition blocked IL-6-induced lncTCF7 upregulation.
qRT-PCR analysis of lncTCF7 in SK-Hep-1 cells cultured in the presence or absence of 5 μM LLL12, a STAT3 inhibitor for 2 h and then with
50 ng/ml IL-6 for an additional 12 h. e SK-Hep-1 cells were transfected with a negative control, 50 nM control siRNA (siCon) or 50 nM STAT3
siRNA (siSTAT3) as described in the Materials and methods. Forty-eight hours after transfection, the cells were treated with 50 ng/ml IL-6 for
12 h. At the end of the cell culture period, cell lysates were prepared for determination STAT3 activation by western blotting. Data are representative
of at least three independent experiments. f The cells were treated as described in section E. At the end of the cell culture period, cells were prepared
for qRT-PCR analysis of lncTCF7 (n = 3)
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study, we identified lncTCF7 as an IL-6-inducible lncRNA
that is vital for the IL-6 mediated malignant phenotype.
lncTCF7, a lncRNA initially identified in HCC, was
reported to be highly expressed in HCC tumors and liver
cancer stem cells (CSCs) [16]. LncTCF7 is necessary for
liver CSC self-renewal and tumor propagation. Mechan-
istically, lncTCF7 recruits the SWI/SNF complex to the
promoter region of TCF7 to regulate its expression,
leading to activation of Wnt signaling [16]. Yet, up
until now, few studies have concentrated on the tran-
scriptional factors that contributes to its upregulation.
In this study, we proposed a link between IL-6/STAT3
signaling and lncTCF7, which are two well-known
driver of malignancy.
We first explored the effect of IL-6 on the expression
of previously identified HCC specific lncRNAs. We
revealed that lncTCF7 was most strongly upregulated in
response to IL-6 stimulation. STAT3, a mediator of
IL-6/STAT3 signaling, is considered to be a potent
oncogene as it is often constitutively activated in most
solid and hematological tumors and exerts multiple pro-
tumorigenic activities, including promotion of tumor cell
proliferation, invasion, metastasis, survival and angiogen-
esis [35–37]. We found that STAT3 is phosphorylated
after IL-6 exposure, and acted a potent transcriptional
factor that directly binds to the promoter region of human
lncTCF7 gene. STAT3 knockdown or inhibiting STAT3
activation abrogated the IL-6-depenendent transcriptional
Fig. 3 lncTCF7 is transcriptionally regulated by STAT3 in response to IL-6 stimulation. a Schematic representation of lncTCF7 promoter with seven
potential SIEs and the primer pair used in ChIP-PCR assays. The reporter construct lncTCF7-Luc and its truncated and mutated derivatives are also
shown. b Transcription activity in response to IL-6 treatmemt for 6 h measured by luciferase assay in SK-Hep-1 cells with a series of deletion
mutants of lncTCF7-luc (internal control, pRL-TK). *p < 0.05. c Relative luciferase activity 6 h after IL-6 incubation in SK-Hep-1 cells transfected
with the wild-type or SIE mutated lncTCF7 promoter reporter construct. *p < 0.05. d Chromatin prepared from SK-Hep-1 cells stimulated with
IL-6 for 1 h was immunoprecipitated with the indicated antibodies; PCR was performed on immunoprecipitated DNAs or soluble chromatin
using specific primer pair for the lncTCF7 promoter
Fig. 4 Effect of IL-6 on the EMT progress in HCC. a Phase-contrast images (left) and immunofluorescence images (right) of SK-Hep-1 cells
stained using antibodies against E-cadherin or Vimentin after treated with or without 50 ng/ml IL-6 for 72 h. b Western-blot analysis of
phenotypic markers after treated with or without 50 ng/ml IL-6 for 72 h in SK-Hep-1 cells
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activation. Functionally, lncTCF7 silencing attenuated
IL-6 induced epithelial-mesenchymal transition and
invasion of HCC cells.
Except for lncTCF7, other studies have identified that
lncRNA HOTAIR as IL-6-inducible lncRNA and may be
involved in IL-6-induced signal transduction in cancer
[38]. These studies, together with ours, suggest that
lncRNAs, which are a group of largely uncharacterized
molecules, may play an important role in the regulation
of IL-6/STAT3 signaling. miRNAs (19–25 nt), another
class of noncoding RNAs, play vital regulatory roles in
cancer mainly at the posttranscriptional level [39–41].
Previous studies have characterized a number of IL-6-
regulated miRNAs in cancer, such as miR-17/19A [39],
miR-21 [40] and miR-34a [41]. Our study expanded the
downstream effectors of IL-6/STAT3 signaling.
Based on the data, we propose a model that depicts a
role of lncTCF7 in the regulation of IL-6-mediated
Fig. 5 lncTCF7 plays a critical role in IL-6 induced EMT. a qRT-PCR analysis of lncTCF7 expression following treatment of SK-Hep-1 cells with
two individual siRNAs targeting lncTCF7. b Morphology of SK-Hep-1 cells with siRNAs against lncTCF7 or scrambled control and stimulated
with 50 ng/mL of IL-6 for 72 h. qRT-PCR analysis (c) and western blots (d) of 72 h IL-6 treated SK-Hep-1 cells receiving the indicated siRNAs
of EMT specific marker E-cadherin and Vimentin. Data represent the mean ± S.D. from three independent experiments.*p < 0.05.*p < 0.05
Fig. 6 lncTCF7 was involved in the IL-6-induced invasiveness of cancer cells. lncTCF7 knockdown inhibited the invasion of SK-Hep-1 cells
and further decreased the IL-6-induced promotion of SK-Hep-1 cell invasiveness. The results suggested that lncTCF7 was also involved in
the IL-6-induced promotion of SK-Hep-1 cell invasiveness. The data represent the mean ± SD of three independent experiments
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aggressive phenotype. This is the first study which
shows that lncTCF7 is an IL-6-inducible lncRNA and
is involved in IL-6 induced epithelial-mesenchymal
transition and invasion of HCC cells. The present
study may also cast light on the prophylactic treat-
ment for the primary HCC.
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